Table I.

Clinical trials of lung cancer immunotherapy using NK cells.

Source of NK cells	Sample size	Stage	Type	Treatment	Styles	Effects	Status	Country	Reference/Clinical Trails.gov Identifier
Autologous	90	Phase II	NSCLC	–	Combined with radiochemotherapy	–	Suspended	Germany	NCT02118415
	104	Phase II	NSCLC	i.v.	Combined with chemotherapy	–	Unknown	China	NCT02734524
	30	Phase I	NSCLC	i.v.	Combined with NKT	–	Unknown	China	NCT03198923
	20	Phase II	NSCLC	i.v.	Combined with programmed cell death-1 antibody	–	Unknown	China	NCT03958097
	24	Phase I/IIa	NSCLC	i.v.	Combined with GC, cetuximab	–	Not yet recruiting	NKMAX Co., Ltd.	NCT04872634
	120	Phase II	SCLC	i.v.	Used alone	–	Unknown	China	NCT03410368
	10	Phase I	Advanced lung adenocarcinoma	i.v.	Used alone	–	Enrolling	China	NCT03662477
Allogeneic	24	Phase I/IIa	NSCLC	i.v.	Combined with Standard Cancer Treatment	–	Not recruiting	China	NCT04616209
	30	Phase I/II	NSCLC	i.v.	Combined with cryosurgery	No toxicities, clinically effective	Completed	China	NCT02843815 (176)
Haploidentical	5	Phase I	NSCLC	central venous catheter	Combined with pemetrexed	–	Completed	Korea	NCT03366064
ANKL	68	Phase II	NSCLC	i.v.	Combined with chemotherapy	–	Unknown	Korea	NCT02370017
NK 92	5	Phase I	NSCLC	i.v.	Used alone	–	Enrolling	China	NCT03656705
NK 012	72	Phase II	SCLC	i.v.	Used alone	–	Completed	Japan	NCT00951613
–	30	Phase II	NSCLC	i.v.	Combined with Cetuximab	–	Completed	China	NCT02845856

NK, natural killer; SCLC, small-cell lung cancer; NSCLC, non-small cell lung cancer.